Lots of positive news: Great effectiveness, easy for any Hep B manufacturer to make, easier storage requirements, and patent-free. > Texas Children’s hospital

Lots of positive news: Great effectiveness, easy for any Hep B manufacturer to make, easier storage requirements, and patent-free. > Texas Children’s hospital said the vaccine was over 90% effective against the original Covid-19 strain and over 80% effective against the Delta variant. The vaccine’s efficacy against the Omicron variant is currently being tested. > “We make the protein, directly and synthetically, in the lab using the yeast system,” Bottazzi explained. “We ask the yeast to make a protein that looks just like a protein that is made by the virus. Then we immunize the protein and the body then processes this protein and presents it to the immune system. Therefore, you don’t ask your body to do any major manipulation of the coding.” > Crucially, storing the Corbevax vaccine only requires standard refrigeration, unlike the Pfizer vaccine, which requires ultra-cold storage in transit. > Biological E, an Indian pharmaceutical company accustomed to producing hepatitis B vaccines with whom Bottazzi’s team has a longstanding relationship, has already produced 150m doses of the new Corbevax vaccine and will soon be able to produce 100m doses every month.